modelPhenylephrineCombination
Extends from Pharmacolibrary.Drugs.ATC.S.S01GA55.
Information
| name: | PhenylephrineCombinations | |
| ATC code: | S01GA55 | route: | ophthalmic |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 3 | L |
| clearance: | 1800 | ml/h/kg |
| other parameters in model implementation | ||
Phenylephrine is an alpha-1 adrenergic receptor agonist commonly used as a mydriatic (to dilate the pupil) and decongestant, often in combination with other agents for ophthalmic use. The ATC code S01GA55 corresponds to combinations containing phenylephrine for ophthalmic application. It is approved and still used in clinical ophthalmology.
Pharmacokinetics
No published pharmacokinetic studies were found specifically for ophthalmic phenylephrine-containing combinations (ATC S01GA55) in humans. Thus, pharmacokinetic parameters are estimated based on known properties of topical phenylephrine in adults.
References
Atkinson, HC, et al., & Anderson, BJ (2015). Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. European journal of clinical pharmacology 71(8) 931–938. DOI:10.1007/s00228-015-1876-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26022219
Seliniotaki, AK, et al., & Mataftsi, A (2022). Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial. Trials 23(1) 322–None. DOI:10.1186/s13063-022-06243-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35428316
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)